Mark Beveridge - Moberg Pharma VP Fin
| MOB Stock | SEK 18.26 0.93 4.85% |
Insider
Mark Beveridge is VP Fin of Moberg Pharma AB
| Age | 45 |
| Phone | 46 8 52 23 07 00 |
| Web | https://www.mobergpharma.se |
Moberg Pharma Management Efficiency
The company has return on total asset (ROA) of (0.0249) % which means that it has lost $0.0249 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0325) %, meaning that it generated substantial loss on money invested by shareholders. Moberg Pharma's management efficiency ratios could be used to measure how well Moberg Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mikael Blomqvist | KABE Group AB | 42 | |
| Anders Vallenljord | IAR Systems Group | 55 | |
| Kajsa Lernestal | eEducation Albert AB | 36 | |
| Marie MSc | Clinical Laserthermia Systems | 44 | |
| Arta Mandegari | eEducation Albert AB | 37 | |
| Dan Mogren | Clinical Laserthermia Systems | N/A | |
| Raquel Tosca | Swedencare publ AB | 49 | |
| Edward Holden | Swedencare publ AB | 42 | |
| Robert Hrd | Mekonomen AB | 57 | |
| Jonas Tidqvist | KABE Group AB | 54 | |
| Johan Skogeryd | KABE Group AB | N/A | |
| Richard Lind | IAR Systems Group | 59 | |
| LarsErik Eriksson | Clinical Laserthermia Systems | 74 | |
| Associate Lindquist | Lipum AB | 63 | |
| Mats Ekelund | Clinical Laserthermia Systems | N/A | |
| Martin Dahlgren | eEducation Albert AB | 30 | |
| Ehsan Yazdani | eEducation Albert AB | 41 | |
| Viktor Trojefors | KABE Group AB | 32 | |
| Jenny Graflind | Swedencare publ AB | 47 | |
| Tim Normann | Norva24 Group AB | 59 | |
| Haydn Povey | IAR Systems Group | 53 | |
Management Performance
| Return On Equity | -0.0325 | |||
| Return On Asset | -0.0249 |
Moberg Pharma AB Leadership Team
Elected by the shareholders, the Moberg Pharma's board of directors comprises two types of representatives: Moberg Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moberg. The board's role is to monitor Moberg Pharma's management team and ensure that shareholders' interests are well served. Moberg Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moberg Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Beveridge, VP Fin | ||
| Anders Broijersen, Chief Officer | ||
| MSc BA, Chief Officer | ||
| Kerstin Strinnholm, Ex Chairman | ||
| Marie Moberg, CoFounder | ||
| Gunilla Wengstrm, Director Marketing |
Moberg Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moberg Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0325 | |||
| Return On Asset | -0.0249 | |||
| Operating Margin | (97.71) % | |||
| Current Valuation | 82.88 M | |||
| Shares Outstanding | 98.27 M | |||
| Shares Owned By Insiders | 18.07 % | |||
| Shares Owned By Institutions | 3.39 % | |||
| Price To Earning | 4.77 X | |||
| Price To Book | 0.42 X | |||
| Price To Sales | 1,098 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Moberg Stock Analysis
When running Moberg Pharma's price analysis, check to measure Moberg Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moberg Pharma is operating at the current time. Most of Moberg Pharma's value examination focuses on studying past and present price action to predict the probability of Moberg Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moberg Pharma's price. Additionally, you may evaluate how the addition of Moberg Pharma to your portfolios can decrease your overall portfolio volatility.